GlassScriptPhysician profile
Amy C Nelson
NPI 1942528104
$6,131.32
in general payments reported to CMS, 2019-2025
38 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,949 · 2022: $1,608 · 2023: $726 · 2024: $690 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.43 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $2,565.03 | 2021 | |
| Celgene Corporation | $532.33 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $512.95 | 2022-2024 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $219.80 | 2022-2024 | |
| Seagen INC. | $207.16 | 2021-2025 | |
| Janssen Biotech, INC. | $180.36 | 2022-2024 | Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $177.56 | 2022-2023 | Pomalyst |
| Ethicon US, LLC | $148.68 | 2022 | |
| Gilead Sciences, INC. | $128.56 | 2022-2023 | Trodelvy |
| Daiichi Sankyo INC. | $124.04 | 2022 | |
| Myriad Genetic Laboratories, INC. | $123.25 | 2023 | Myrisk |
| Eisai INC. | $121.95 | 2024 | |
| Incyte Corporation | $105.10 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.92 | 2022 | |
| Merck Sharp & Dohme LLC | $95.71 | 2022-2024 | Keytruda |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $94.38 | 2023 | Orserdu |
| Genentech USA, INC. | $74.33 | 2022 | |
| Amgen INC. | $66.39 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $61.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.45 | 2022-2024 | |
| Csl Behring | $43.05 | 2022-2025 | Idelvion, Afstyla |
| Eusa Pharma (US) LLC | $38.61 | 2022 | |
| Sun Pharmaceutical Industries INC. | $35.65 | 2022-2025 | |
| Lilly USA, LLC | $35.41 | 2022 | |
| Genmab U.S., INC. | $34.42 | 2024 | Epkinly |
| Pfizer INC. | $28.09 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.45 | 2024 | |
| Array Biopharma INC | $23.15 | 2025 | Mektovi, Tukysa, Braftovi |
| Amag Pharmaceuticals, INC. | $21.38 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.35 | 2022 | |
| Emd Serono, INC. | $20.51 | 2022 | |
| G1 Therapeutics, INC. | $19.57 | 2022 | |
| Geron Corporation | $18.61 | 2024 | Rytelo |
| Morphosys, US INC. | $18.34 | 2022 | |
| Taiho Oncology, INC. | $17.74 | 2022 | |
| Genzyme Corporation | $15.25 | 2024 | |
| Glaxosmithkline, LLC. | $14.45 | 2022 | |
| Ge Healthcare | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.